Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Survivin as a Therapeutic Target in Squamous Cell Carcinoma

  • Chapter
  • First Online:
Squamous cell Carcinoma

Abstract

Survivin is a universal tumor marker that belongs to inhibitor of apoptosis protein (IAP) family. It is involved in the control of cell cycle and inhibition of apoptosis. As like other cancers, most of the SCCs also overexpress survivin gene. Tumors overexpressing survivin generally bear a poor prognosis and are associated with resistance to therapy. The differential expression of survivin in cancer versus normal tissues makes it a useful tool in cancer diagnosis and a promising therapeutic target. Disruption of the survivin induction pathway has resulted in an increase in apoptosis and inhibition of tumor growth. In this chapter, we will discuss recent advances in cancer therapeutics targeting survivin gene.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agada FO, Patmore H, Alhamarneh O et al (2009) Genetic profile of head and neck squamous cell carcinoma: clinical implications. J Laryngol Otol 123:266–272

    Article  CAS  PubMed  Google Scholar 

  • Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 12:542–547

    Article  Google Scholar 

  • Altieri DC (2003a) Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5:447–452

    PubMed  Google Scholar 

  • Altieri DC (2003b) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54

    Article  CAS  PubMed  Google Scholar 

  • Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921

    Article  CAS  PubMed  Google Scholar 

  • Andersen MH, Thor SP (2002) Survivin-A universal tumor antigen. Histol Histopathol 17:669–675

    CAS  PubMed  Google Scholar 

  • Andersen MH, Pedersen LO, Capeller B et al (2001a) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964–5968

    CAS  PubMed  Google Scholar 

  • Andersen MH, Pedersen LO, Becker JC et al (2001b) Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res 61:869–872

    CAS  PubMed  Google Scholar 

  • Ansell SM, Arendt BK, Grote DM et al (2004) Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin’s lymphoma. Leukemia 18:616–623

    Article  CAS  PubMed  Google Scholar 

  • Atikcan S, Unsal E, Demirag F et al (2006) Correlation between survivin expression and prognosis in non-small cell lung cancer. Respir Med 100:2220–2226

    Article  PubMed  Google Scholar 

  • Caldas H, Jiang Y, Holloway MP et al (2005) Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24:1994–2007

    Article  CAS  PubMed  Google Scholar 

  • Chen YF, Chen FJ, Fang Y et al (2004) Survivin expression in laryngeal squamous cell carcinoma and its relationship with clinical factors. Ai Zheng 23:1493–1497

    PubMed  Google Scholar 

  • Chen X-Q, Yang S, Li Z-Y et al (2012) Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. Mol Med Rep 5:917–922

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chih-Ching Wu, Chang Y-T, Chang K-P et al (2014) Salivary auto-antibodies as noninvasive diagnostic markers of oral cavity squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965

    Google Scholar 

  • Choi KS, Lee TH, Jung MH (2003) Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 10:87–95

    Article  CAS  PubMed  Google Scholar 

  • Chuunyao X, Zhidong X, Xiaocheng Y et al (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1:687–694

    Google Scholar 

  • Crook NE, Clem RJ, Miller LK (1993) An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 67:2168–2174

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dallaglio K, Marconi A, Pincelli C (2012) Survivin: a dual player in healthy and diseased skin. J Invest Dermatol 132:18–27

    Article  CAS  PubMed  Google Scholar 

  • Dallaglio K, Petrachi T, Marconi A et al (2014) Expression of nuclear survivin in normal skin and squamous cell carcinoma: a possible role in tumour invasion. Br J Cancer 110:199–207

    Article  CAS  PubMed  Google Scholar 

  • De Schepper S, Bruwiere H, Verhult T et al (2003) Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J Pharmacol Exp Ther 304:881–888

    Article  PubMed  CAS  Google Scholar 

  • Deveraux QL, Takahashi R, Salvesen GS et al (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300–304

    Article  CAS  PubMed  Google Scholar 

  • Deveraux QL, Roy N, Stennicke HR et al (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17:2215–2223

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dong Y, Sui L, Watanabe Y et al (2002) Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 22:2377–2383

    PubMed  Google Scholar 

  • Falleni M, Pellegrini C, Marchetti A et al (2003) Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200:620–626

    Article  CAS  PubMed  Google Scholar 

  • Fei G, Sigua C, Tao J et al (2004) Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64:2580–2589

    Article  Google Scholar 

  • Fei Q, Zhang H, Fu L et al (2008) Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. Acta Biochim Biophys Sin (Shanghai) 40:466–477

    Article  CAS  Google Scholar 

  • Friedrichs B, Siegel S, Andersen MH et al (2006) Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk Lymphoma 47:978–985

    Article  CAS  PubMed  Google Scholar 

  • Fukuda S, Louis M (2006) Pelus. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5:1087–1098

    Article  CAS  PubMed  Google Scholar 

  • Giodini A, Kallio MJ, Wall NR et al (2002) Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62:2462–2467

    CAS  PubMed  Google Scholar 

  • Gold DP, Shroeder K, Golding A et al (1997) T-cell receptor peptides as immunotherapy for autoimmune disease. Crit Rev Immunol 17:507–510

    CAS  PubMed  Google Scholar 

  • Grabowski P, Kuhnel T, Muhr-Wilkenshoff F et al (2003) Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88:115–119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grossman D, McNiff JM, Li F et al (1999) Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 79:1121–1126

    CAS  PubMed  Google Scholar 

  • Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349–352

    Article  CAS  PubMed  Google Scholar 

  • Guan J, Chen J, Luo Y et al (2002) Effects of antisense bcl2 or survivin on the growth of neuroblastoma cell line SK-N-MC. Zhonghua Yi Xue Za Zhi 82:1536–1540

    CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Article  CAS  PubMed  Google Scholar 

  • Haseloff J, Gerlach WL (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334:585–591

    Article  CAS  PubMed  Google Scholar 

  • Hassing CA, Schreiber SL (1999) Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1:300–308

    Article  Google Scholar 

  • Hayashi N, Asano K, Suzuki H et al (2005) Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 65:10–19

    Article  CAS  PubMed  Google Scholar 

  • Hirohashi Y, Torigoe T, Maeda A et al (2002) An HLA-A24-restricted cytotoxic T lympho-cyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8:1731–1739

    CAS  PubMed  Google Scholar 

  • Huang H-K, Bailis JM, Leversaon JD et al (2005) Suppressor of Bir1P (survivin) identify roles for the chromosomal passenger protein Pic1P (INCNP) and the replication initiation factor Psf2P in chromosome segregation. Mol Cell Biol 25:9000–9015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ikeguchi M, Kaibara N (2002) Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 87:883–887

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074–1080

    Article  CAS  PubMed  Google Scholar 

  • Jiang G, Li Jinlong, Zeng Z et al (2006) Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 5:435–440

    Article  CAS  PubMed  Google Scholar 

  • Johnson DH, Blot WJ, Carbone DP et al (2008) Cancer of the lung: non-small cell lung cancer and small cell lung cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, et al. (eds) Abeloff’s Clinical oncology, 4th ed. Elsevier Churchill Livingstone, Philadelphia (Chap 76)

    Google Scholar 

  • Johnston WK, Unrau PJ, Lawrence MS et al (2001) RNA-catalyzed RNA polymerization: accurate and general RNA-templated primer extension. Science 292:1319–1325

    Article  CAS  PubMed  Google Scholar 

  • Kaitan S, Mendosa M, Jantch-Plunger V et al (2000) INCENP and Aurora like kinase form a complex essential for chromosom segregation and efficient completion of cytokinesis. Curr Biol 10:1072–1081

    Google Scholar 

  • Kanwar JR, Shen WP, Kanwar RK et al (2001) Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93:1541–1552

    Article  CAS  PubMed  Google Scholar 

  • Kato J, Kuwabara Y, Mitani M et al (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92–95

    Article  CAS  PubMed  Google Scholar 

  • Khan Z, Bisen PS (2013) Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta 1836:123–145

    CAS  PubMed  Google Scholar 

  • Khan Z, Bhadouria P, Gupta R et al (2006) Tumor control by manipulation of the human anti-apoptotic survivin gene. Curr Cancer Ther Rev 2:73–79

    Article  CAS  Google Scholar 

  • Khan Z, Tiwari RP, Mulherkar R et al (2009) Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. Head Neck 31:1039–1048

    Article  PubMed  Google Scholar 

  • Khan Z, Khan N, Tiwari RP et al (2010a) Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 96:267–273

    Article  CAS  PubMed  Google Scholar 

  • Khan Z, Khan N, Varma AK et al (2010b) Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel. Curr Cancer Drug Targets 10:660–669

    Article  CAS  PubMed  Google Scholar 

  • Khan Z, Tiwari RP, Khan N et al (2012) Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression. Curr Gene Ther 12:444–453

    Article  CAS  PubMed  Google Scholar 

  • Knauer SK, Bier C, Schlag P et al (2007) The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 6:1502–1509

    CAS  PubMed  Google Scholar 

  • Kouzarides T (1999) Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9:40–48

    Article  CAS  PubMed  Google Scholar 

  • Lee JP, Chang KH, Han JH et al (2005) Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors. Int J Gynecol Cancer 15:113–119

    Article  PubMed  Google Scholar 

  • Lens SM, Rodriguez JA, Vader G et al (2006) Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell 17:1897–1909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–583

    Google Scholar 

  • Li DW, Gao S, Shen B et al (2011) Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma. Med Oncol 28(Suppl 1):S333–S340

    Article  PubMed  CAS  Google Scholar 

  • Ling X, Li F (2004) Silencing of anti-apoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques 36:450–454

    CAS  PubMed  Google Scholar 

  • Liu H, Guo S, Roll R et al (2007) Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther 6:697–704

    Article  CAS  PubMed  Google Scholar 

  • Lo Muzio L, Pannone G, Staibano S et al (2003) Survivin expression in oral squamous cell carcinoma. Br J Cancer 89:2244–2248

    Google Scholar 

  • Lo Muzio L, Farina A, Rubini C et al (2005) Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 225:27–33

    Google Scholar 

  • Lu D, Qian J, Yin X et al (2012) Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci 69:143–146

    CAS  PubMed  Google Scholar 

  • Mahotka C, Liebman J, Wenzel M et al (2002) Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9:1334–1342

    Article  CAS  PubMed  Google Scholar 

  • Mara F, Jonet P, Sophie C et al (2003) Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278:50402–50411

    Article  Google Scholar 

  • Marinkovich MP (2007) Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat Rev Cancer 7:370–380

    Article  CAS  PubMed  Google Scholar 

  • Mehra R (2014) Biomarkers in HPV negative squamous-cell carcinomas of head, neck. AACR Annual Meeting, April 8, San Diego, CA

    Google Scholar 

  • Mehra R, Zhu F, Yang DH et al (2013) Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res 19:6633–6643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mesri M, Wall NR, Li J et al (2001) Cancer gene therapy using a survivin mutant adenovi-rus. J Clin Invest 108:981–990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mirza A, McGuirk M, Hockenberry TN et al (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613–2622

    Article  CAS  PubMed  Google Scholar 

  • Miyazaki A, Kobayashi J, Torigoe T et al (2011) Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 102:324–329

    Article  CAS  PubMed  Google Scholar 

  • Muzio LL, Staibano S, Pannone G et al (2001) Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol 70:249–254

    Google Scholar 

  • Olie RA, Simoes-Wust AP, Baumann B et al (2000) A novel anti-sense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805–2809

    CAS  PubMed  Google Scholar 

  • Pennati M, Binda M, Colella G et al (2003) Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120:648–654

    Article  CAS  PubMed  Google Scholar 

  • Pennati M, Binda M, Colella G et al (2004) Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23:386–394

    Article  CAS  PubMed  Google Scholar 

  • Pisarev V, Yu B, Salup R et al (2003) Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9:6523–6533

    CAS  PubMed  Google Scholar 

  • Pizem J, Cor A, Gale N (2004) Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 45:180–186

    Article  CAS  PubMed  Google Scholar 

  • Pley HW, Flaherty KM, McKay DB (1994) Three-dimensional structure of a hammerhead ribozyme. Nature 372:68–74

    Article  CAS  PubMed  Google Scholar 

  • Reed JC (1998) Bcl-2 family proteins. Oncogene 17:3225–3236

    Article  PubMed  Google Scholar 

  • Reker S, Becker JC, Svane IM et al (2004) HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 108:937–941

    Article  CAS  PubMed  Google Scholar 

  • Ridky TW (2007) Nonmelanoma skin cancer. J Am Acad Dermatol 57:484–501

    Article  PubMed  Google Scholar 

  • Rothenberg SM, Ellisen LW (2012) The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 122:1951–1957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sah NK, Khan Z, Khan GJ et al (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164–171

    Article  CAS  PubMed  Google Scholar 

  • Santarelli A, Mascitti M, Lo Russo L et al (2013) Detection level of salivary survivin in patients with OSCC. J Carcinogene Mutagene S5

    Google Scholar 

  • Scaffidi C, Fulda S, Srinivasan A et al (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675–1687

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scheper MA, Nikitakis NG, Sauk JJ (2007) Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg 36(7):632–639

    Article  CAS  PubMed  Google Scholar 

  • Schmidt SM, Schag K, Muller MR et al (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102:571–576

    Article  CAS  PubMed  Google Scholar 

  • Schmitz M, Diestelkoetter P, Weigle B et al (2000) Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60:4845–4849

    CAS  PubMed  Google Scholar 

  • Shui PT, Jiang XH, Lin MCM et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724–7732

    Google Scholar 

  • Siegel S, Wagner A, Schmitz N (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911–914

    Article  PubMed  Google Scholar 

  • Skoufias DA, Mollinari C, Lacroix FB et al (2000) Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151:1575–1581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278:23130–23140

    Article  CAS  PubMed  Google Scholar 

  • Stoleriu MG, Steger V, Mustafi M et al (2014) A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3. Eur J Cardiothorac Surg. doi:10.1093/ejcts/ezu087

    PubMed  Google Scholar 

  • Su L, Wang Y, Xiao M et al (2010) Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110:484–491

    Article  PubMed  Google Scholar 

  • Sullivan SM (1994) Development of ribozymes for gene therapy. J Invest Dermatol 103:85S–89S

    Article  CAS  PubMed  Google Scholar 

  • Sun ZJ, Zhang L, Hall B et al (2012) Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 18:5304–5313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Takeno S, Yamashita S, Takahashi Y et al (2010) Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression. Eur J Cardiothorac Surg 37:440–445

    PubMed  Google Scholar 

  • Tamm I, Wang Y, Sausville E et al (1998) IAP family protein survivin inhibits caspase activity and apoptosis induced by fas (CD95), bax, caspases, and anti-cancer drugs. Cancer Res 58:5315–5320

    CAS  PubMed  Google Scholar 

  • Tetsuhiro T, Fumitake H, Toshihiko F et al (2004) Phase I clinical study of anti-apoptosis protein, survivin derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2:19

    Article  CAS  Google Scholar 

  • Tu SP, Cui JT, Liston P et al (2005) Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 128:361–375

    Article  CAS  PubMed  Google Scholar 

  • Turksma AW, Bontkes HJ, Ruizendaal JJ et al (2013) Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med 11:152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Uchida H, Tanaka T, Sasaki K et al (2004) Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10:162–171

    Article  CAS  PubMed  Google Scholar 

  • Uren AG, Wong L, Pakusch M et al (2000) Survivin and the inner centromere protein INCENP show similar cell cycle localization and gene knockout phenotype. Curr Biol 10:1319–1328

    Article  CAS  PubMed  Google Scholar 

  • Vaux DL, Haecker G, Strasser A (1994) An evolutionary perspective apoptosis. Cell 76:777–779

    Article  CAS  PubMed  Google Scholar 

  • Veness MJ (2007) High-risk cutaneous squamous cell carcinoma of the head and neck. J Biomed Biotechnol 2007:80572

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Verdicia MA, Huang H, Dutil E et al (2000) Structure of human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 7:602–608

    Article  CAS  Google Scholar 

  • Vivek R, Kannan S, Achiraman S et al (2011) Survivin deficiency leads to imparalization of cytokinesis in cancer cells. Asian Pac J Cancer Prev 12:1675–1679

    PubMed  Google Scholar 

  • Wang Y, Zhu H, Quan L, Zhou C, Bai J, Zhang G, Zhan Q, Xu N (2005) Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther 4(9):974–978

    Article  CAS  PubMed  Google Scholar 

  • Wen LJ, Gao LF, Jin CS et al (2013) Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo. Int J Clin Exp Pathol 6:2071–2081

    PubMed  PubMed Central  Google Scholar 

  • Wheatley SP, McNeish IA (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247:35–88

    Article  CAS  PubMed  Google Scholar 

  • Wochner A, Attwater J, Coulson A et al (2011) Ribozyme-catalyzed transcription of an active ribozyme. Science 332:209–212

    Article  CAS  PubMed  Google Scholar 

  • Wu X, Wang L, Schroer S et al (2009) Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice. Diabetologia 52:2130–2141

    Article  CAS  PubMed  Google Scholar 

  • Xu GC, Zhang P, Leng F et al (2012) Inhibition of lymphatic metastases by a survivin dominant-negative mutant. Oncol Res 20:579–587

    Article  PubMed  CAS  Google Scholar 

  • Yamamoto T, Manome Y, Miyamoto A et al (2003) Development of novel gene therapy using survivin anti-sense expressing adenoviral vectors [in Japanese]. Gan To Kagaku Ryoho 30:1805–1808

    CAS  PubMed  Google Scholar 

  • Yang YL, Li XM (2000) The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10:169–177

    Article  CAS  PubMed  Google Scholar 

  • Yang G, Huang AL, Tang N et al (2003) Inhibition of survivin expression in liver cancer cells by shRNA. Zhonghua Gan Zang Bing Za Zhi 11:712–715

    Google Scholar 

  • Yoshida H, Sumi T, Hyun Y et al (2003) Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Oncol Rep 10:45–49

    CAS  PubMed  Google Scholar 

  • Young JC, Hoogenraad NJ, Hart FU (2003) Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell 112:41–50

    Article  CAS  PubMed  Google Scholar 

  • Yu DD, Wang CT, Shi HS et al (2010) Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant. J Exp Clin Cancer Res 12(29):46

    Article  CAS  Google Scholar 

  • Yuan QZ, Wang CT, Mao YQ et al (2010) Enhanced tumor radiosensitivity by a survivin dominant-negative mutant. Oncol Rep 23:97–103

    PubMed  Google Scholar 

  • Zhang M, Latham DE, Delaney MA et al (2005) Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24:2474–2482

    Article  CAS  PubMed  Google Scholar 

  • Zhang R, Wang T, Li KN et al (2008) A survivin double point mutant has potent inhibitory effect on the growth of hepatocellular cancer cells. Cancer Biol Ther 7:547–554

    Article  CAS  PubMed  Google Scholar 

  • Zhang LQ, Wang J, Jiang F et al (2012) Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS ONE 7:e34100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu HX, Zhou CQ, Zang G et al (2003) Survivin mutants reverse the malignancy of HeLa cells. Ai Zheng 22:467–470

    CAS  PubMed  Google Scholar 

  • Zhu H, Wang Q, Hu C et al (2011) High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol 32:1147–1153

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA

    Zakir Khan

Authors
  1. Zakir Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zakir Khan .

Editor information

Editors and Affiliations

  1. Oral Medicine, King's College London Oral Medicine, Surrey, United Kingdom

    Saman Warnakulasuriya

  2. Cedars-Sinai Medical Center, Department of Biomedical Sciences Cedars-Sinai Medical Center, Los Angeles, California, USA

    Zakir Khan

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Khan, Z. (2017). Survivin as a Therapeutic Target in Squamous Cell Carcinoma. In: Warnakulasuriya, S., Khan, Z. (eds) Squamous cell Carcinoma. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-1084-6_8

Download citation

Publish with us

Policies and ethics

Search

Navigation